Fewer than one in 10 patients that would benefit from obesity jabs including Wegovy can access them, caution the World Health Organization as it releases its first recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for broader and more equitable access to GLP-1 medication.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our new guidance acknowledges that obesity is a long-term condition that can be addressed with holistic and continuous treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are key hurdles to broad access to the jabs that can help people shift substantial body mass, says the organization.
Skinny Jab Supply Crisis
Even under the present best projected outlook, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, per the health organization.
The advice calls on governments and firms to increase access, by strategies including voluntary licensing.
Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is set to lapse in several countries in 2026.
How Obesity Injections Function
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so people reduce food intake.
Individuals commonly begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence indicates users may regain a significant portion after a year of halting the treatment, because their typical appetite return.
To be carrying excess weight elevates your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and specific cancers.
Excess weight concerns individuals in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
